These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

362 related articles for article (PubMed ID: 15046537)

  • 21. Effects of selective serotonin and serotonin/noradrenaline reuptake inhibitors on extracellular serotonin in rat diencephalon and frontal cortex.
    Felton TM; Kang TB; Hjorth S; Auerbach SB
    Naunyn Schmiedebergs Arch Pharmacol; 2003 Mar; 367(3):297-305. PubMed ID: 12644903
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinically relevant pharmacology of selective serotonin reuptake inhibitors. An overview with emphasis on pharmacokinetics and effects on oxidative drug metabolism.
    Preskorn SH
    Clin Pharmacokinet; 1997; 32 Suppl 1():1-21. PubMed ID: 9068931
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of 5-HT(6) receptor blockade on the neurochemical outcome of antidepressant treatment in the frontal cortex of the rat.
    Dawson LA; Li P
    J Neural Transm (Vienna); 2003 Jun; 110(6):577-90. PubMed ID: 12768354
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Serotonin and Norepinephrine Reuptake Inhibitors.
    Shelton RC
    Handb Exp Pharmacol; 2019; 250():145-180. PubMed ID: 30838456
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Recent pharmacologic advances in antidepressant therapy.
    Kilts CD
    Am J Med; 1994 Dec; 97(6A):3S-12S. PubMed ID: 7992824
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In the treatment of depression, does selectivity of action matter?
    J Clin Psychiatry; 2004; 65 Suppl 4():60-2. PubMed ID: 15046543
    [No Abstract]   [Full Text] [Related]  

  • 27. Neurokinin1 antagonists potentiate antidepressant properties of serotonin reuptake inhibitors, yet blunt their anxiogenic actions: a neurochemical, electrophysiological, and behavioral characterization.
    Gobert A; Brocco M; Dekeyne A; Di Cara B; Bouchez G; Lejeune F; Gannon RL; Millan MJ
    Neuropsychopharmacology; 2009 Mar; 34(4):1039-56. PubMed ID: 18830239
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Future directions for serotonin and antidepressants.
    Artigas F
    ACS Chem Neurosci; 2013 Jan; 4(1):5-8. PubMed ID: 23336036
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of the effects of antidepressants on norepinephrine and serotonin concentrations in the rat frontal cortex: an in-vivo microdialysis study.
    Beyer CE; Boikess S; Luo B; Dawson LA
    J Psychopharmacol; 2002 Dec; 16(4):297-304. PubMed ID: 12503828
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Synaptic effects of antidepressants.
    Richelson E
    J Clin Psychopharmacol; 1996 Jun; 16(3 Suppl 2):1S-7S; discussion 7S-9S. PubMed ID: 8784643
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Recent Developments on Future Antidepressant-related Serotonin Receptors.
    Amidfar M; Kim YK
    Curr Pharm Des; 2018; 24(22):2541-2548. PubMed ID: 30073919
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Mechanism of action of antidepressant drugs: importance of genetically modified mice in the pharmacological in vivo approach].
    Gardier A
    Therapie; 2005; 60(5):469-76. PubMed ID: 16433012
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Neuropharmacological and antidepressant-like effects of ZY-1408: A novel serotonin/norepinephrine reuptake inhibitor and serotonin receptor 2C antagonist.
    Gao N; Tiliwaerde M; Zheng W; Xiong J; Li X; Jin Z
    Neuropharmacology; 2021 Jan; 182():108376. PubMed ID: 33122031
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical and biochemical effects of catecholamine depletion on antidepressant-induced remission of depression.
    Miller HL; Delgado PL; Salomon RM; Berman R; Krystal JH; Heninger GR; Charney DS
    Arch Gen Psychiatry; 1996 Feb; 53(2):117-28. PubMed ID: 8629887
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacological and behavioral characterization of D-473, an orally active triple reuptake inhibitor targeting dopamine, serotonin and norepinephrine transporters.
    Dutta AK; Santra S; Sharma H; Voshavar C; Xu L; Mabrouk O; Antonio T; Reith ME
    PLoS One; 2014; 9(11):e113420. PubMed ID: 25427177
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of the effects of antidepressants and their metabolites on reuptake of biogenic amines and on receptor binding.
    Sánchez C; Hyttel J
    Cell Mol Neurobiol; 1999 Aug; 19(4):467-89. PubMed ID: 10379421
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antidepressants that inhibit both serotonin and norepinephrine reuptake impair long-term potentiation in hippocampus.
    Cooke JD; Cavender HM; Lima HK; Grover LM
    Psychopharmacology (Berl); 2014 Dec; 231(23):4429-41. PubMed ID: 24781518
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antidepressant-like pharmacological profile of a novel triple reuptake inhibitor, (1S,2S)-3-(methylamino)-2-(naphthalen-2-yl)-1-phenylpropan-1-ol (PRC200-SS).
    Liang Y; Shaw AM; Boules M; Briody S; Robinson J; Oliveros A; Blazar E; Williams K; Zhang Y; Carlier PR; Richelson E
    J Pharmacol Exp Ther; 2008 Nov; 327(2):573-83. PubMed ID: 18689611
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Interplay between the key proteins of serotonin system in SSRI antidepressants efficacy.
    Kulikov AV; Gainetdinov RR; Ponimaskin E; Kalueff AV; Naumenko VS; Popova NK
    Expert Opin Ther Targets; 2018 Apr; 22(4):319-330. PubMed ID: 29542343
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Development of new antidepressants.
    Sambunaris A; Hesselink JK; Pinder R; Panagides J; Stahl SM
    J Clin Psychiatry; 1997; 58 Suppl 6():40-53. PubMed ID: 9227672
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.